KDM5 family members (A, B, C and D) that demethylate H3K4me3 have been shown to be involved in human cancers. Here we performed screening for KDM5A inhibitors from chemical libraries using the AlphaScreen method and identified a battery of screening hits that inhibited recombinant KDM5A. These compounds were further subjected to cell-based screening using a reporter gene that responded to KDM5A inhibition and 6 compounds were obtained as candidate inhibitors. When further confirmation of their inhibition activity on cellular KDM5A was made by immunostaining H3K4me3 in KDM5A-overexpressing cells, ryuvidine clearly repressed H3K4me3 demethylation. Ryuvidine prevented generation of gefitinib-tolerant human small-cell lung cancer PC9 cells and also inhibited the growth of the drug-tolerant cells at concentrations that did not affect the growth of parental PC9 cells. Ryuvidine inhibited not only KDM5A but also recombinant KDM5B and C; KDM5B was the most sensitive to the inhibitor. These results warrant that ryuvidine may serve as a lead compound for KDM5 targeted therapeutics.
Fe(II)-dependent hydroxylation, and KDM1 enzymes remove methyl groups via flavin-dependent monoamine oxidation.
Numerous studies have shown that KDM5 family members (KDM5A/JARID1A/RBP2 [7] [8] [9] [10] [11] [12] [13] [14] , KDM5B/ JARID1B/PLU-1 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , KDM5C/JARID1C/SMCX [25] [26] [27] [28] [29] [30] and KDM5D/JARID1D/SMCY [30] [31] [32] ) play a role in oncogenesis. Furthermore, these enzymes have also been shown to mediate drug tolerance in cancer 10, 23, [33] [34] [35] [36] . These findings have encouraged the development of KDM5 inhibitors 37, 38 . Indeed, some compounds that show promise as potential drugs have been reported [39] [40] [41] [42] [43] [44] [45] .
Here we performed screening of KDM5A inhibitors from small molecule libraries using AlphaScreen technology and identified a battery of screening hits. Further cell-based screening assays narrowed these hits to a panel of potential KDM5A inhibitors. We show that ryuvidine, one of the identified inhibitors in this study, repressed the growth of drug-resistant cells derived from the PC9 non-small-cell lung cancer (NSCLC) cell line.
Results
In vitro screening of KDM5A inhibitors. A schematic of the screening strategy using AlphaScreen technology (PerkinElmer) that we used to identify KDM5A inhibitors is shown in Supplementary Fig. 1A . KDMA5Acatalyzed demethylation of biotinylated H3K4me3 peptide produces biotinylated H3K4me2 and H3K4me1. These products selectively bind to the acceptor beads coated with antibody against H3K4me2/me1 peptides and also bind to the streptavidin-coated donor beads via biotin in the peptides, producing a ternary complex of peptide-acceptor bead-donor bead. A photosensitizer in the donor bead generates singlet oxygen upon excitation at 680 nm and the singlet oxygen excites a chromophore in the acceptor bead in the ternary complex, emitting light at around 615 nm. In this experiment, we used an antibody that recognizes both H3K4me2 and H3K4me1 peptides.
His-tagged KDM5A1-797 was produced in Sf9 insect cells and affinity purified using the His tag. Kinetic analyses, including the dependency of the reaction on enzyme quantity, reaction time, and concentrations of cofactors (2-OG and Fe(II)) and substrate, confirmed that the purified KDM5A was suitable for screening for inhibitors ( Supplementary Fig. 1B -F).
We screened 3,865 small molecules from known drug libraries (Microsource International Drug, MicroSource US Drug, Prestwick, and Tocris, the libraries consisting molecules with known effects on biological processes). We selected 60 compounds that showed inhibition rates higher than 70% at 5 μM. In the standard assay condition, Fe(II) was included at 3 μM. We confirmed that the inhibitory activity of the 60 compounds was not significantly repressed in the presence of 50 μM Fe(II), which excluded the possibility that the compounds exhibited inhibitory effects through chelating Fe(II) or competing with Fe(II).
Cell-based screening of KDM5A inhibitors. To identify KDM5A inhibitors that function in cells, we developed a reporter assay in which inhibitor-mediated activation of a promoter increased luciferase reporter activity.
We first conducted cDNA microarray analysis on mRNA from PC9 parental cells and KDM5A-overexpressing PC9 cells and found that TFPI-2 (tissue factor pathway inhibitor-2) mRNA was reduced to 19% in KDM5A-overexpressing cells ( Supplementary Table 1 ). We also previously demonstrated that knockdown of LSD1 and LSD2 in HEK293 cells induced TFPI-2 expression 46 . Together these findings suggest that the TFPI-2 promoter may respond to KDM5A inhibitors.
To validate this possibility, we performed knockdown of the KDM5A gene in HEK293 cells by transfection with two siRNAs. Both siRNA85 and siRNA86 significantly decreased KDM5A mRNA compared with negative control siRNA ( Fig. 1A ) with a parallel increase in TFPI-2 mRNA ( Fig. 1B) . Western blotting confirmed that KDM5A was reduced upon siRNA-mediated knockdown (Fig. 1C ), while TFPI-2 was elevated ( Fig. 1D ). The doublet bands of TFPI-2 reflect differential glycosylation 47 . These results suggest that expression of a TFPI2 promoter-directed reporter luciferase gene may respond to KDM5A inhibitors.
We then constructed a reporter plasmid in which the human TFPI-2 promoter region (−513 to +53) was subcloned upstream of the luciferase gene. A stable HEK293 clone, HEK293TFPI-2-Luc cells that harboured the reporter plasmid was established, and we then examined whether the reporter responded to knockdown of KDM5A. Indeed, knockdown of KDM5A by siRNA significantly elevated the expression of luciferase and, as expected from our previous result 46 , knockdown of LSD1 by siRNA10 also increased reporter expression ( Fig. 2A ). We next examined whether the reporter responded to a known KDM5A inhibitor (PBIT) that inhibits cellular KDM5A 39 . PBIT induced reporter expression in a dose-dependent manner ( Fig. 2B ), validating that this reporter assay would enable screening KDM5A inhibitors that function in cells. Notably, an LSD inhibitor (NCL-1) 46, 48, 49 also increased the reporter activity ( Fig. 2C ), indicating this assay is responsive to inhibitors for LSD as well as KDM5A.
The 60 identified compounds were subjected to the reporter assay. We selected 10 compounds that increased luciferase activity by more than two-fold at 10 μM (Table 1) . Table 1 also includes their IC 50 values determined by AlphaScreen technology. A dose-dependent inhibition curve to measure IC 50 is shown in Supplementary Fig. 2 , which shows the inhibition curve of ryuvidine as a representative compound.
MALDI-TOF/MS assay. As mentioned above, the selected compounds may have inhibition activity on LSD.
Recombinant LSD1 and LSD2 were prepared and assayed with each of the compounds (at 20 μM) using the MALDI-TOF/MS method, as described previously 50 . Only thimerosal significantly inhibited LSD activity, and the other 9 compounds showed no effects. Thimerosal, therefore, was not used in the subsequent experiments.
To confirm that these 9 compounds inhibited KDM5A, we used the H3K4me3 peptide as substrate and examined enzyme reaction products (H3K4me2/H3K4me1 peptides) using the MALDI-TOF/MS method. The enzyme reaction was dependent on the presence of cofactors (Fe(II) and 2-OG) and reaction time, validating this method Immunostaining of HEK293 cells overexpressing Flag-tagged KDM5A. To examine whether the selected inhibitors could prevent reduction of H3K4me3 in cells overexpressing KDM5A, we transiently expressed Flag-tagged KDM5A in HEK293 cells and performed immunostaining with antibodies against Flag and H3K4me3. In Flag-negative cells, H3K4me3 was detected, while H3K4me3 was undetectable in Flag-positive cells ( Fig. 4) . Notably, when treated with ryuvidine, H3K4me3 was clearly detected in Flag-positive cells. These results suggest that the overexpressed KDM5A demethylated H3K4me3 and ryuvidine prevented the reduction of H3K4me3 through inhibition of KDM5A. However, the other 5 compounds (NSC95397, tolonium chloride, methylene blue, pyrithione zinc and auranofin) did not show clear repression of the reduction of H3K4me3 ( Supplementary Fig. 6 ), although they induced luciferase activity in the reporter assay. This discrepancy between ryuvidine and other compounds remains to be studied.
Drug-resistant non-small-cell lung cancer PC9 cells. PC9 cells express a mutant form of EGFR (epi-
dermal growth factor receptor) with a 15 bp deletion in exon 9 (E746-A750), resulting in a constitutively active form of EGFR-TK (EGFR-tyrosine kinase) 51 . Gefitinib was developed as an EGFR-TK inhibitor and remarkably reduces tumour growth in many lung cancer patients; however, a drug-resistant cancer cell population emerges after treatment, resulting in recurrence of the disease. Sharma et al. 33 found that most PC9 cells cultured in the presence of high concentration of gefitinib died, but a small population of the cells could survive and proliferate, giving rise to drug-tolerant cells, called DTEPs (drug-tolerant expanded persisters). Further analyses of DTEPs suggested that the elevated expression of KDM5A was attributable to the appearance of these drug-tolerant cells. www.nature.com/scientificreports www.nature.com/scientificreports/ We next considered whether the KDM5A inhibitors may repress growth of DTEPs more efficiently than parental PC9 cells. To address this question, we prepared DTEPs according to the reported procedures 33 . When PC9 cells were cultured in the presence of high concentration of gefitinib (2 μM) for 3 days, most of the cells died, but a small population of cells survived and continued growing ( Supplementary Fig. 7A ). We continued to culture these cells for 2 months with 2 μM gefitinib, and the resulting cells were used as DTEPs. Small but reproducible increases of KDM5A mRNA and demethylase activity were observed in DTEPs compared with parental PC9 cells ( Supplementary Fig. 7B and C). DTEPs were resistant to various concentrations of gefitinib, while parental PC9 cells quickly died under these conditions ( Supplementary Fig. 7D ). In addition to deletion of exon 9, other EGFR mutations (L858R and T790M) giving rise to gefitinib-resistant cells were identified in NSCLC 52, 53 . We confirmed Supplementary Fig. 2 where dose-dependent inhibition by ryuvidine is shown). These compounds increased luciferase activity of the cell-based reporter assay by more than two-fold at 10 μM.
www.nature.com/scientificreports www.nature.com/scientificreports/ that the exon 9 deletion in EGFR was present in both PC9 cells and DTEPs and that both cell lines were absence for the L858R and T790M mutations.
We next examined the effects of KDM5A inhibitors on the growth of PC9 cells and DTEPs. Remarkably, ryuvidine inhibited the growth of DTEPs at concentrations in which PC9 cells were mostly unaffected (Fig. 5A ). Other 5 compounds, however, did not show marked differential effects on PC9 and DTEPs ( Supplementary  Fig. 8 ). Furthermore, co-treatment of gefitinib and ryuvidine in PC9 cultures impeded generation of DTEPs colonies (Fig. 5B ).
Specificity of ryuvidine inhibition. We next examined the specificity of ryuvidine in inhibiting other
KDM5 family members. Ryuvidine inhibited KDM5A, B, and C with different efficiencies ( Table 2 ). KDM5B was the most sensitive to ryuvidine, whereas KDM5C showed more resistance to the drug. LSD activities were not inhibited at a high concentration of ryuvidine (50 μM).
Discussion
To identify small molecules that inhibit KDM5A, we used AlphaScreen technology to screen drug libraries consisting of 3,865 compounds with known effects on cells and obtained 60 compounds that were positive in the in vitro assay. These compounds were subjected to further evaluation using a reporter assay to determine their ability to inhibit cellular KDM5A. The reporter assay was based on our finding that siRNA-mediated knockdown of KDM5A in HEK293 cells increased TFPI-2 expression. We prepared an HEK293 clone that harboured a reporter plasmid in which luciferase expression was under control of the TFPI-2 promoter region (−513 to +53). www.nature.com/scientificreports www.nature.com/scientificreports/ H3K4me3 is generally increased in the promoters of transcribed genes and thought to be a marker for activated transcription, but only in a subset of genes 38 . We have not yet determined the precise sequence(s) in the TFPI-2 promoter that are responsible for KDM5A knockdown-mediated activation of reporter expression.
We selected the 10 compounds that significantly induced the activity of our reporter by more than two-fold in the luciferase reporter assay. Four compounds (thimerosal, BVT948, proflavine hemisulfate and nitroxoline) were excluded, because thimersal strongly inhibited LSDs and the other three compounds inhibited KDM5A activity through competing with 2-OG, a cofactor of KDM5A. The chemical structures of the final 6 compounds are shown in Supplementary Fig. 9 . We examined whether these compounds acted on cellular KDM5A using immunostaining in cells overexpressing KDM5A, and found that only ryuvidine clearly repressed the reduction of H3K4me3(see Fig. 4 ).
NSCLC-derived PC9 cells are sensitive to the EGFR-TK inhibitor gefitinib, and extended culture of PC9 in the presence of high concentration of the drug produces drug-resistant cells, DTEPs. Induction of KDM5A during culture is responsible for occurrence of the drug tolerance 33 . We confirmed these observations (see Supplementary Fig. 7 ) and examined the effects of the selected compounds on the growth of DTEPs. Interestingly, ryuvidine inhibited growth of DTEPs at concentrations where growth of parental PC9 was unaffected. Other 5 inhibitors did not show differential effects on both cell types, suggesting that they are toxic. Previous studies have reported that ryuvidine exhibits cytotoxicity by inhibiting CDK4 54 , CDC7 kinase 55 and SETD8/KMT5A (H3K20 monomethyltransferase) 56 . As these inhibitions are not observed in parental PC9 cells, the contribution of these events to ryuvidine-derived growth inhibition of DTEPs is unlikely. However, the possibility has not been excluded that some of these enzymes in DTEPs have become more sensitive to ryuvidine inhibition than in PC9 cells.
Drug-tolerant cells may be caused by mutations that render key proteins insensitive to drugs and/or activation of an alternative pathway for cell growth. We confirmed that the DTEPs used in this study did not harbour previously identified mutations (L858R and T790M) that make EGFR insensitive to gefitinib. Some studies have reported activation of alternative pathways in gefitinib-tolerant PC9 cells, such as the IGF-1 receptor pathway 33,57 , www.nature.com/scientificreports www.nature.com/scientificreports/ Akt-β-catenin pathway 58 and FGF2-FGF receptor 1 autocrine pathway 59 , suggesting diverse drug-resistance mechanisms in PC9 cells 60 . We have not yet explored the molecular mechanism(s) by which our DTEPs emerged.
Although ryuvidine is a compound with known effects on cells, our findings indicate that ryuvidine may be a useful lead chemical for the generation of a new class of KDM5 inhibitors. Chemical modifications of ryuvidine to improve the specificity and efficacy as an H3K4me3me2 demethylase inhibitor are warranted. Poor permeation into cells may be a widespread mechanism that underlies modest performance of a drug. We have shown that conjugation of a proteasome inhibitor (ridaifen-F) to a cell-penetrating peptide markedly elevates the inhibition of cellular proteasome through accelerated uptake 61 , suggesting modification point of ryuvidine. Intracellular modifications would also impair drug efficacy. Ryuvidine, a derivative of benzothiazoledione, may be reduced by the cellular dione system, converting into a compound with low efficacy. This suggests another point for modification of ryuvidine.
Our results showed that NSC95397 inhibited KDM5A at much lower concentrations compared with the other identified compounds (see Table 1 ). However, this compound did not induce luciferase activity in the reporter assay, suggesting that it might be difficult for NSC95397 to penetrate into cells. Chemical modifications of this compound including conjugation with a cell-penetration peptide might dramatically improve its inhibitory potency of cellular KDM5A. , 100 μg/mL streptomycin, and 100 U/mL penicillin at 37 °C in a humidified 5% CO 2 incubator. PC9 cells and PC9-derived DTEPs were cultured in RPMI1640 medium containing the supplements described above.
Materials and Methods

Production of His-tagged KDM5 proteins in Sf9 insect cells and purification.
Sf-9 cells were infected with baculovirus expressing N-terminally hexahistidine-tagged and C-terminal truncated human KDM5 proteins (KDM5A 1-797, KDM5B 1-769 and KDM5C 1-839). After culture for three days at 28 °C, cells were harvested and lysed. Lysate was cleared by centrifugation, and the supernatant was applied to a HisTrap HP column (0.7 × 2.5 cm) (GE Healthcare) equilibrated with buffer A (20 mM sodium phosphate buffer, pH 7.5, containing 0.5 M NaCl, 40 mM imidazole, 10 mM 2-mercaptoethanol). Elution was performed by linearly increasing the concentration of imidazole from 40 to 500 mM in buffer A. Fractions enriched in enzyme activity were collected and concentrated.
AlphaScreen method for KDM5A assay. The assay buffer consisted of 50 mM HEPES-KOH pH 7.5, 0.1% BSA, and 0.01% Tween 20. A 0.1-μl sample of compound solution dissolved in DMSO or DMSO alone was spotted into the wells of an AlphaPlate-384 SW (6008350, PerkinElmer) using the EDR-384 UX multi-channel pipettor (BioTec). Assay buffer (5 μl) containing 10 nM His-tagged KDM5A was dispensed into the wells using the mini-Gene LD-01 dispenser (BioTec). The plates were incubated for approximately 20 min at room temperature. Reactions were initiated by the addition of 5 μl of assay buffer containing 60 nM biotinylated H3K4me3 peptide, 80 μM 2-OG, 200 μM ascorbate, and 6 μM (NH4) 2 Fe(SO 4 )·6H 2 O. The final concentrations of each compound from the known drug libraries were 5 μM in the reaction mixture, respectively. As background, 2-OG was omitted from the reaction mixture. The plates were incubated at 26 °C for 1 h and then 8 μl of 1X AlphaLISA Epigenetics Buffer 1 (AL008F, PerkinElmer), containing 22.5 μg/ml anti-H3K4me1-2 AlphaLISA acceptor beads (AL116R, PerkinElmer), 22.5 μg/ml streptavidin-coated donor beads (6760002B, PerkinElmer), and 16.9 mM EDTA (Alpha beads mixture) were added. The plate was incubated at 23 °C overnight. Luminescence was measured using the EnSpire Alpha plate reader (PerkinElmer).
To measure background values, the reactions were run without 2-OG. The control values measured by running the reactions in the absence of compounds were defined as 100% activity. The sample values were measured by running the reactions with a compound for screening. In all mixtures, DMSO was added at final 1%. Inhibition (%) by a compound was calculated as 100 × [1 − (sample-background)/(control-background)].
Prior to experiments, the assay was optimized for reaction time and concentrations of the reaction components ( Supplementary Fig. 1B-F ).
Luciferase reporter assay. Genomic DNA was isolated from HeLa cells using the Gentra Puregene
Cell Kit. The human TFPI-2 gene 5′ flanking region from −513 to +53 (where +1 is the first transcription start site) was amplified by PCR using HeLa genomic DNA as a template with the forward primer 5′-AATACTCGAGCTGTCCACCTACGATATATTATAAGCCTGT-3′ and reverse primer 5′-TATGAAGCTTGCTGGGCAAGGCGTCCGAGAAAGC-3′. The underlined text indicates restriction enzyme sites for Xho I and Hind III, respectively. The amplified fragment was subcloned into the Xho I and Hind III sites of the luciferase reporter plasmid pGL4.17 to generate the TFPI2-Luc plasmid.
HEK293 cells were transfected with the TFPI2-Luc plasmid using Lipofectamine 2000 reagent. G418-resistant colonies were cloned and propagated in selective medium containing 0.6 mg/ml G418. One of the stable clones that stably expressed the TFPI2-Luc plasmid was used and referred to as HEK293TFPI2-Luc cells.
HEK293TFPI2-Luc cells were seeded at 3 × 10 4 cells per well in a 96-well plate in 0.1 ml of DMEM containing 10% FBS. After 24 h, the cells were treated as indicated. Cells were washed with PBS and lysed with 20 μl of Passive
